| ID Source | ID |
|---|---|
| PubMed CID | 41718 |
| CHEMBL ID | 3560248 |
| SCHEMBL ID | 5933954 |
| MeSH ID | M0111174 |
| Synonym |
|---|
| terbufos-sulfone |
| 56070-16-7 |
| phosphorodithioic acid, s-(((1,1-dimethyethyl)sulfonyl)methyl) o,o-diethyl ester |
| terbufos sulfone |
| unii-u2v9fry9p2 |
| u2v9fry9p2 , |
| phosphorodithioic acid, s-((1,1-dimethylethyl)sulfonylmethyl) o,o-diethyl ester |
| SCHEMBL5933954 |
| o,o-diethyl s-(tert-butylsulfonyl)methyl phosphorodithioate |
| s-[(tert-butylsulfonyl)methyl] o,o-diethyl dithiophosphate # |
| tox21_304046 |
| dtxcid9022443 |
| NCGC00357253-01 |
| dtxsid1042443 , |
| cas-56070-16-7 |
| CHEMBL3560248 |
| terbufos sulphone |
| terbufos-sulfone, pestanal(r), analytical standard |
| terbufos-sulfone 100 microg/ml in acetonitrile |
| terbufossulfone |
| tert-butylsulfonylmethylsulfanyl-diethoxy-sulfanylidene-lambda5-phosphane |
| terbufos-sulfone 1000 microg/ml in acetone |
| Q27290604 |
Terbufos, terbufos sulfoxide and ter bufos sulfone were highly toxic to C. Study aimed to investigate the result of non-observable adverse effect level dose of a highly toxic OPC.
| Excerpt | Reference | Relevance |
|---|---|---|
| " The present study aimed to investigate the result of non-observable adverse effect level dose of a highly toxic OPC, terbufos sulfone (TBS), on sub-chronic exposure on the status of proinflammatory cytokines; interleukin-1β, interleukin-6 and tumor necrosis factor-α in rats brain." | ( Sub-chronic exposure of non-observable adverse effect dose of terbufos sulfone: neuroinflammation in diabetic and non-diabetic rats. Adeghate, E; Adem, A; Kamal, MA; Nurulain, SM; Ojha, S; Sharma, C; Sheikh, A; Yasin, J, 2014) | 0.85 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In search for more efficacious and broad-spectrum alternatives, we have assessed in vivo the mortality-reducing efficacy of a group of five compounds with known AChE inhibitory activity (pyridostigmine, physostigmine, ranitidine, tacrine and K-27), when given in equitoxic dosage (25% of LD01 ) 30 min before exposure to the OPC terbufos sulfone." | ( Prophylactic administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using terbufos sulfone. Hasan, MY; Kuča, K; Lorke, DE; Nurulain, SM; Petroianu, GA, 2014) | 0.78 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 49.2823 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 17.3432 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 60.0123 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 61.1306 | 0.0010 | 22.6508 | 76.6163 | AID1224839 |
| progesterone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 43.2771 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 43.2885 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1259401 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 9.6885 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 76.9588 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 43.6412 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 126.7930 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 76.9588 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 76.9588 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.33) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||